EZH2 and Miyoshi myopathy: Inhibition of EZH2 sensitizes MM to bortezomib treatment in vivo, through cooperative MYC suppression and inhibition of H3K27 trimethylation to regulate genes involved in B cell metabolism and antibody production [22,23].